Woodstock Corp Buys 1,825 Shares of Eli Lilly and Company $LLY

Woodstock Corp lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 18.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,972 shares of the company’s stock after purchasing an additional 1,825 shares during the period. Woodstock Corp’s holdings in Eli Lilly and Company were worth $9,135,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $8,827,714,000. Jennison Associates LLC boosted its holdings in Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after acquiring an additional 226,620 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in Eli Lilly and Company by 7.9% in the first quarter. Alliancebernstein L.P. now owns 5,443,919 shares of the company’s stock worth $4,496,187,000 after purchasing an additional 397,696 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $886.00 to $1,104.00 in a report on Monday, November 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, BMO Capital Markets set a $1,200.00 price objective on Eli Lilly and Company in a report on Thursday, December 4th. Four investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Buy” and an average price target of $1,141.73.

Eli Lilly and Company Price Performance

LLY opened at $1,042.06 on Thursday. The company has a fifty day simple moving average of $951.95 and a 200 day simple moving average of $826.51. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market cap of $985.14 billion, a P/E ratio of 50.98, a P/E/G ratio of 1.32 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.